2019 funded projects

In 2019, EBRP approved the following 18 projects along with continuation funding for our 21-center EB Clinical Research Consortium and funding of a bioprinter for Dr. Jakub Tolar's work at the University of Minnesota, totaling nearly $8.5M. These projects are funded in partnership with EB Research Foundation of Australia, EB Medical Research Foundation, and Cure EB.

INSTITUTION	PROJECT NAME	PRINCIPAL INVESTIGATOR(S)	AMOUNT AWARDED
​​Columbia University	​Development of a drug testing platform for recessive dystrophic epidermolysis bullosa squamous cell carcinoma using induced pluripotent cancer cells	​Joanna Jackow PhD	​$551,250
​​Neem Biotech Limited	Identification of ajoene analogues for the treatment of epidermolysis bullosa	Tracy Nevitt PhD	​$112,400 ​
​​Thomas Jefferson University	Targeting fibrosis for RDEB therapy in preclinical animal models	Andrew South PhD	​$159,054
​​University of Colorado	A Comprehensive Stem Cell Biobank for EB Patients	Ganna Bilousova PhD Anna L. Bruckner MD Dennis R Roop PhD Igor Kogut PhD	$286,815
​University of Minnesota	Next Generation Genome Editing for RDEB	Jakub Tolar MD PhD	​$1,000,000
​​University of Colorado	​​A cGMP-Compliant Library Master Cell Bank as a Necessary Prerequisite for an iPSC-Based Clinical Trial for EB	​Igor Kogut PhD Ganna Bilousova PhD Dennis R Roop PhD	​$964,176
​University of Colorado	Developing an iPS Cell-based Therapy for Epidermolysis Bullosa Simplex	​Dennis R Roop PhD Ganna Bilousova PhD Igor Kogut PhD Anna Bruckner MD	​​$518,638
​​Université du Québec à Chicoutimi	Inactivation of epidermolysis bullosa simplex dominant mutations by allele-specific CRISPR/Cas9	Catherine Laprise PhD Lucie Germain PhD Jacques-P Tremblay PhD	​​$255,400
Wings Therapeutics	Clinical Development of QR-313 for treatment of DEB	Mark De Souza, PhD	$1,500,000
University of Southern California	Optimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in JEB Patients with Nonsense Mutations	Mei Chen PhD ​David Woodley MD	$254,300
Stanford University	Topical and intradermal recombinant type VII collagen protein replacement therapy for recessive dystrophic epidermolysis bullosa: A placebo controlled Phase 1 clinical trial	M. Peter Marinkovich MD Jean Tang MD PhD David Olsen PhD ​Gerhard Bauer PhD	$350,000
Stanford University	DISCOVER-JEB study for demystifying the causes of early lethality in generalized-severe Junctional Epidermolysis Bullosa due to Laminin-332 mutations	M. Peter Marinkovich MD Vamsi Krishna Yenamandra MD PhD Irina Gurevich PhD ​Kerriann M Casey DVM DACVP	$127,000
Stanford University	Computational Drug Repurposing for Epidermolysis Bullosa Simplex	Joyce Teng MD PhD ​Kavita Sarin MD PhD	$187,782
Centre for Human Genetics	Development of a Registry for Epidermolysis Bullosa in India	Ravi Hiremagalore MD, Gurudatta Baraka PhD Arun Inamadar MD ​Sacchidanand MD	$35,620
University College Dublin	Development of gene-editing therapy to restore Type VII Collagen for the treatment of RDEB using a topical RNP CRISPR system	Wenxin Wang PhD	​$117,053.44
Thomas Jefferson University	Epidermolysis Bullosa Community Cell Bank	Andrew South PhD	$151,651
Stanford University	GMP Manufacturing of Autologous Esophageal Epithelial cells for the Prevention of Esophageal Strictures	Anthony Oro MD PhD	$300,421
​FIBRX Derm	Development of Human Recombinant Decorin Core Protein as a Topical Anti-Scarring Therapy for Dystrophic Epidermolysis Bullosa	​Professor Jean Tang, MD, PhD	$1,250,000